Special Issue "Immunomodulatory Effects of Drugs for Cancer Immunotherapy"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 1213
Special Issue Editors
Interests: cancer immunotherapy; drug repositioning; multiple myeloma; prostate cancer
Special Issue Information
Dear Colleagues,
Recent advances in cancer immunotherapy, including those in immune checkpoint inhibitors (ICIs) or adoptive T-cell therapies, have contributed to better outcomes in cancer patients. However, even ICIs are ineffective in the treatment of certain cancers. Therefore, new strategies to enhance the efficacy of treatments are needed. It has been reported that several commonly used drugs, such as statin, exert immune-modulatory effects; due to such properties, these drugs are expected to enhance the body’s immunity against cancer cells.
This Special Issue aims to further develop the current body of literature on the current knowledge regarding the immunomodulatory effects of a wide variety of drugs, which will aid the advancement and development of cancer therapy.
We are inviting submissions of review or original articles on all aspects of “Immunomodulatory Effects of Drugs for Cancer Immunotherapy”.
Dr. Maiko Matsushita
Dr. Takeshi Suzuki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- immunomodulatory
- immunostimulatory
- drug
- drug repositioning
- chemotherapeutic agents.
